全文获取类型
收费全文 | 42篇 |
免费 | 1篇 |
国内免费 | 28篇 |
专业分类
基础医学 | 1篇 |
临床医学 | 7篇 |
内科学 | 2篇 |
外科学 | 28篇 |
综合类 | 16篇 |
预防医学 | 4篇 |
药学 | 7篇 |
中国医学 | 5篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 2篇 |
2023年 | 5篇 |
2022年 | 1篇 |
2019年 | 2篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2013年 | 4篇 |
2012年 | 4篇 |
2011年 | 4篇 |
2010年 | 4篇 |
2009年 | 9篇 |
2008年 | 4篇 |
2007年 | 4篇 |
2006年 | 9篇 |
2005年 | 1篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 5篇 |
2001年 | 1篇 |
2000年 | 2篇 |
1988年 | 1篇 |
排序方式: 共有71条查询结果,搜索用时 31 毫秒
1.
Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt. 相似文献
2.
Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt. 相似文献
3.
Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt. 相似文献
4.
5.
通心络胶囊治疗缺血性脑血管病35例 总被引:3,自引:0,他引:3
目的:观察通心络胶囊治疗缺血性脑血管病的临床观察。方法:将65例缺血性脑血管患者随机分为治疗组和对照组,其中治疗组35例,采用通心络胶囊(由石家庄以岭药业有限公司生产)治疗,口服每次4粒,日3次,对照组30例,给予尼莫地平片剂(由德国拜耳公司生产)治疗。口服每次30mg,日3次,均治疗4周为1疗程,采用单盲法给药。结果;通心络胶囊对缺血性脑血管病能明显改善临床症状及体征,治疗组显效17例(48.5%),有效15例(43.0%),无效3例(8.5%),总有效率91.5%;对照组显效12例(40%),有效12例(40%),无效6例(20%),总有效率80%;两组经统计学处理,有显著性差异,治疗组疗效明显优于对照组(P<0.05)。同时通心络胶囊可显著降低胆固醇,甘油三脂水平,改善血液流变学指标,并有91.5%的病例经过治疗后局部脑血流灌注显像(SPECT)显示局部脑血灌注损伤较治疗前明显改善。结论:通心络胶囊对缺血性脑血管病的气虚血瘀,脉络瘀阻等所致的半身不遂,口舌歪斜,语言不利,偏身麻木不仁等症状具有较好的疗效以及能降低血清胆固醇,甘油三酯,改善血液流变学指标和改善脑供血。 相似文献
6.
目的:探讨神经松动术结合常规康复训练对卒中后不同阶段偏瘫患者手功能恢复的疗效。方法:脑卒中偏瘫患者102例,根据卒中后时间分为1月组(46例),2月组(32例),3月组(24例);3组均行神经松动术结合常规康复训练3个月。于治疗前、训练1、3个月分别采用Fugl-Meyer上肢运动量表(FMA-U)、偏瘫上肢功能测试(FTHUE)、改良Barthel指数(m BI)和日常生活活动能力(ADL)评价偏瘫手精细动作、运动协调能力、感觉功能、日常生活能力等。于治疗后1、3月部分患者行静息状态下fMRI扫描检测中央前回第一运动区激活情况。结果:治疗前,3组各量表评分差异无统计学意义(P0.05)。治疗1、3个月后,各组FMA、FTHUE、MBI和ADL评分均较同组治疗前改善(P0.05);其中,1月组各评分统计学差异最显著(P0.01)。治疗1、3个月后,中央前回第一运动区信号强度明显升高,1月组最明显(P0.01)。结论:神经松动术结合常规康复训练能有效的促进脑卒中偏瘫患者手运动功能的恢复,对卒中早期患者疗效更好。 相似文献
7.
目的 研究syndecan-4对碱性成纤维细胞生长因子(bFGF)诱导人肾小球系膜细胞(HMC)增殖及细胞外基质(ECM)分泌的影响,并探讨syndecan-4-蛋白激酶Cα(PKCα)途径在其中的作用。 方法 免疫荧光方法观察syndecan-4在HMC上的表达。筛选有效的syndecan-4-siRNA转染HMC,噻唑蓝(MTT)比色法检测HMC在bFGF不同作用时间下的增殖差异;ELISA法检测细胞上清液中的Ⅰ、Ⅳ型胶原和纤连蛋白(FN)含量;荧光定量PCR观察syndecan-4和PKCα含量的变化。 结果 syndecan-4蛋白在HMC有表达。bFGF可促进HMC的增殖及FN、Ⅳ型胶原的分泌,使得每百万看家基因中PKCα拷贝数明显增加。转染syndecan-4 siRNA后,显著降低了HMC的增殖速度(48~60 h时点,P < 0.01)、ECM分泌(FN:24 h时点,P < 0.01,48~96 h,P < 0.05;Ⅳ型胶原:72~96 h时点,P < 0.05)及PKCα含量 (0 h时点,P < 0.05,12 ~48 h时点,P < 0.01)。 结论 syndecan-4参与调控bFGF诱导HMC的增殖及ECM分泌过程。syndecan-4-PKCα途径可能在其中扮演重要作用。 相似文献
8.
Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt. 相似文献
9.
目的 建立新西兰白兔眼组织中伏立康唑浓度的测定方法,并应用于玻璃体腔注射伏立康唑的眼组织分布研究。方法 采用高效液相色谱-串联质谱(HPLC-MS/MS)法测定兔眼组织中伏立康唑浓度。以甲苯磺丁脲为内标,色谱柱为Waters X-Bridge BEH C18(50 mm×2.1 mm,2.5 μm),流动相A:0.2%甲酸-水溶液;流动相B:0.2%甲酸-乙腈溶液;梯度洗脱程序:0~0.30 min,30% B;0.30~1.81 min,30%→90% B;1.81~2.30 min,90% B;2.30~2.31 min,90%→30% B;2.31~2.60 min,30% B;体积流量为0.5 mL·min-1,柱温30℃,进样量1 μL。使用电喷雾离子源,以多重反应监测方式进行正离子扫描,用于定量分析的离子对分别为m/z 350.1→281.1(伏立康唑)、m/z 271.1→155.0(内标)。新西兰白兔按照体质量、性别随机区间分成5组,每组6只,雌雄各半。无菌条件下,新西兰白兔眼部散瞳,im氯胺酮12 mg·kg-1、赛拉嗪3 mg·kg-1麻醉动物,玻璃体腔注入伏立康唑眼用注射剂,分别在行玻璃体腔注射术后的0.5、1.0、4.0、24.0、48.0 h,过量麻醉后放血处死试验兔。冰浴条件下分离兔眼组织(结膜、角膜、房水、虹膜、晶体、玻璃体、视网膜、脉络膜、巩膜),采用建立的HPLC-MS/MS测定各组织中伏立康唑浓度。结果 伏立康唑质量浓度在0.5~500.0 ng·mL-1,线性关系良好(R2>0.98),定量下限为0.5 ng·mL-1。批内精密度(RSD)和准确度(RE)均小于15%,伏立康唑各眼组织的提取回收率均大于85%;新西兰白兔单眼单次给予伏立康唑后,其主要在眼后段分布,且视网膜浓度相对玻璃体、脉络膜更高。结论 建立的伏立康唑测定方法分析时间短,能够快速检测眼组织中的药物,准确度和灵敏度高,适用于伏立康唑在眼组织的分布研究。 相似文献
10.
Objective To investigate the effect of rosiglitazone on p38 mitogen-activated protein kinase (p38MAPK) pathway in polycystic kidney cyst-lining epithelial cells. Methods The cyst-lining epithelial cells (PKD cells) from human polycystic kidney were treated with rosiglitazone (10 μmol/L), peroxisome proliferator-activated receptor-γ (PPARγ) inhibitor GW9662 (10 μmol/L), rosiglitazone (10 μmol/L) +GW9662 (10 μmol/L), p38MAPK specific inhibitor SB203580 (10 μmol/L), SB203580 (10 μmol/L)+ rosiglitazone(10 μmol/L) for 2 hours followed by epidermal growth factor (EGF) stimulation. Protein expressions of p38, phuspho-p38 (p-p38) and proliferating cell nuclear antigen (PCNA) were detected by Western blot. p38 mRNA was examined by RT-PCR. Expression of c-fos and c-jun was observed by immunocytochemistry. Results (1) EGF markedly up-regulated the expressions of p38, p-p38, PCNA, c-fos anti c-jun compared with control group (P<0.01). (2) Compared with EGF treated group, rosiglitazone significantly reduced p38 activation and mRNA expression (P<0.01, respectively). Rosiglitazone, rosiglitazone+SB203580 could significantly down-regulated p-p38, PCNA, c-fos and c-jun expression (P<0.01, respectively) with no significant difference between these two groups. (3) GW9662 partially reversed the reduction effect of rosiglitazone. Conclusions Rosiglitazone can inhibit proliferation of autosomal dominant polycystic kidney disease cyst-lining epithelial cells partially through down-regulating p38 activation and reducing c-fos, c-jun and PCNA expression. The above effect of rosiglitazone is in part PPARγ-independcnt. 相似文献